 |
|
|
|
||||||
|
 |
|
|
||||||
 |
|||||||||
|
|
||||||||
|
|
|
||
|
|
|
||
|
|
|
||
|
 |
|
||
|
Pharmaceuticals: US Products |
|
||
|
|
|
||
|
Consumers: | |
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
FDA APPROVES NEW ONCE-A-MONTH DOSE OF ACTONEL FOR POSTMENOPAUSAL OSTEOPOROSIS | |
||
|
|
|
||
|
CINCINNATI, Bridgewater, NJ, April 24, 2008 — The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel® (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis. More:   |
|
||
|
|
|
||
|
 |
|
||
|
|
|
||
|
|
|
||
|
||||||
|
|
||||||||||||||||||||
|
|
||||||||||||||||||||
|
|
|
|
|
|||||||||||||||||
|
|
||||||||||||||||||||
